2025-10-10T10:16:41-05:00 2025-03-31 881478669 CBIZ ADVISORS LLC 1899 L STREET NW 850 WASHINGTON DC 20036 990 2024-04-01 760514428 MELANOMA RESEARCH FOUNDATION MELA 2023479675 1420 K STREET NW 7TH FLOOR WASHINGTON DC 20005 KYLEIGH LIPIRA CEO 2023479675 2025-10-10 1 1 FRANK SMITH P00639053 2022274000 2025-10-10 2024 2025-03-06 01:10:19Z KYLEIGH LIPIRA 1420 K STREET NW 7TH FLOOR WASHINGTON DC 20005 8638859 0 X WWW.MELANOMA.ORG X 1996 TX TO ERADICATE MELANOMA BY ACCELERATING MEDICAL RESEARCH WHILE EDUCATING AND ADVOCATING FOR THE MELANOMA COMMUNITY. 12 10 24 340 0 0 8303636 8089338 0 0 242977 118973 -772051 -794486 7774562 7413825 1849954 1629606 0 0 2112375 2363261 0 0 897511 2734890 2912907 6697219 6905774 1077343 508051 7270872 8283039 2821971 3344115 4448901 4938924 THE MRF IS THE LARGEST INDEPENDENT ORGANIZATION DEVOTED TO MELANOMA. ITS MISSION IS TO ERADICATE MELANOMA BY ACCELERATING MEDICAL RESEARCH WHILE EDUCATING AND ADVOCATING FOR THE MELANOMA COMMUNITY. 0 0 2947330 1629606 THE MRF IS COMMITTED TO ADVANCING A BROAD SCIENTIFIC AGENDA ACROSS THE DISCIPLINES OF PREVENTION, DIAGNOSIS, AND TREATMENT. ALTHOUGH THE MRF HAS ACHIEVED A NUMBER OF IMPORTANT SCIENTIFIC MILESTONES, MUCH MORE WORK REMAINS TO BE DONE. TO THIS END, THE MRF FUNDS A SPECTRUM OF RESEARCH GRANTS, SCIENTIFIC INITIATIVES, AND PROGRAMS FOR CUTANEOUS MELANOMA AND RARER MELANOMA SUBTYPES (E.G. OCULAR, PEDIATRIC, ACRAL AND MUCOSAL MELANOMA). ITS RESEARCH GRANT PROGRAM IS A COMPETITIVE, PEER-REVIEWED RESEARCH GRANT PROGRAM FOR INVESTIGATOR-INITIATED RESEARCH HAS BEEN IN EXISTENCE SINCE 1998. MRF-SUPPORTED RESEARCH IS OPEN TO MEDICAL STUDENTS THROUGH SENIOR INVESTIGATIVE TEAMS. 1099138 THE MRF'S ADVOCACY PROGRAM IS A PLATFORM FOR THOSE AFFECTED BY MELANOMA TO SHARE THEIR VOICE AND TRANSFORM POLICY. THE ADVOCACY AGENDA FOCUSES ON ISSUES ON BOTH THE STATE AND FEDERAL LEVEL. THE MAIN PILLARS OF THE PROGRAM ARE ACCESS, PREVENTION, EDUCATION AND FEDERAL FUNDING FOR MELANOMA RESEARCH. 876088 THE MRF HAS A ROBUST EDUCATION PROGRAM AIMED AT EDUCATING PATIENTS, PHYSICIANS AND THE GENEREAL PUBLIC ON PREVENTION, DIAGNOSIS, AND TREATMENT OF MELANOMA, AS WELL AS INCREASING OVERALL AWARENESS OF THE DISEASE. PROGRAMS INCLUDE WEBINARS, EDUCATIONAL MATERIALS, ANIMATED MELANOMA PATIENT VIDEOS, PATIENT/CAREGIVER SYMPOSIUMS AND RESOURCES SUCH AS SUPPORT GROUPS, CLINICAL TRIAL FINDER, TREATMENT CENTER FINDER AND ACCESS TO AN ONCOLOGY NURSE FOR NAVIGATION. 4922556 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 1 1 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 62 0 1 24 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 12 10 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 AL AR CA CO FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NY NC ND OH PA RI SC TN VA WV WI X X KYLEIGH LIPIRA 2023479675 1420 K STREET NW 7TH FLOOR WASHINGTON DC 20005 KYLEIGH LIPIRA CEO 40.00 X X 340283 0 12212 DOUGLAS BRODMAN CHAIR 2.00 X X 0 0 0 THOMAS WESTDYK SECRETARY AND GOVERNANCE 2.00 X X 0 0 0 JILL WROBEL TREASURER 2.00 X X 0 0 0 STAN ADLER BOARD MEMBER - UNTIL 12/2024 1.00 X 0 0 0 MICHAEL B ATKINS MD SAC CO-CHAIR 1.00 X 0 0 0 ELISE BARISH BOARD MEMBER 1.00 X 0 0 0 LAURA FERRIS MD BOARD MEMBER - UNTIL 12/2024 1.00 X 0 0 0 KRISTINA GARGIULO BOARD MEMBER 1.00 X 0 0 0 REBECCA HARTMAN MD BOARD MEMBER - AS OF 01/25 1.00 X 0 0 0 MICHELLE HENRY MD BOARD MEMBER - AS OF 01/25 1.00 X 0 0 0 GIULIA NEWTON BOARD MEMBER 1.00 X 0 0 0 PATTY POPHAL BOARD MEMBER - AS OF 01/25 1.00 X 0 0 0 ASHANI WEERARATNA MD SAC CO-CHAIR 1.00 X 0 0 0 JAMES MERRICK CHIEF COMMUNICATIONS OFFICER 40.00 X 159361 0 12250 ELIZABETH REILLY SR DEVEL OFFICER - ENDOWMENT & PLANNED GIVING 40.00 X 121058 0 18815 JESSICA ALLISON DIRECTOR OF CORPORATE RELATIONS 40.00 X 116635 0 13682 737337 0 56959 4 0 1 0 BLACKBAUD PO BOX 830413 PHILADELPHIA PA 19182 DONOR DATABASE & ACCOUNTING SUPPORT 227912 CLIFTONLARSONALLEN LLP 202 S 6TH STREET SUITE 300 MINNEAPOLIS MN 55402 OUTSOURCED ACCOUNTING SERVICES 213147 CPS EVENTS AT THE PLAZA 770 FIFTH AVENUE 3RD FLOOR NEW YORK NY 10019 GALA VENUE 164123 SARA SELIG 24 HALIFAX STREET SUITE 1 JAMAICA PLAIN MA 02130 CURE OM SUPPORT 163701 STAN ADLER ASSOCIATES 15 WEST 38TH STREET STE 510 NEW YORK NY 10018 GRAPHIC DESIGN AND PRODUCTION SERVICES 150237 7 2313788 5775550 230101 8089338 72789 72789 20000 0 20000 20000 20000 98104 105875 53632 104163 44472 1712 46184 46184 252753 2313788 1067239 -814486 -814486 7413825 0 0 -675513 X 1555858 1555858 45000 45000 28748 28748 390631 246098 27344 117189 1632540 1109272 434196 89072 36522 24873 9943 1706 151356 101517 35006 14833 152212 102007 34867 15338 5879 5879 258888 188009 30200 40679 18589 18589 1064048 654426 210104 199518 67715 39312 13503 14900 315806 192324 49657 73825 428252 222045 99533 106674 39351 20403 9146 9802 279927 220616 19013 40298 121845 19918 101927 223358 119315 50047 53996 12359 6408 2872 3079 MEMBERSHIP DUES 31114 18063 6204 6847 RECOGNITION/AWARDS 26957 15650 5375 5932 STAFF DEVELOPMENT 18819 12612 4311 1896 6905774 4922556 1085707 897511 22223 462948 71038 393324 3900412 1587212 269601 284107 689310 476602 214562 212708 1706411 3378893 1086625 1963847 7270872 8283039 416597 508046 1007941 1635193 1397433 1200876 2821971 3344115 X 1009170 1185628 3439731 3753296 4448901 4938924 7270872 8283039 X 508051 -49450 31422 X 0 1 X 1 0 X 5117283 6964814 7217360 8303636 8089338 35692431 5117283 6964814 7217360 8303636 8089338 35692431 7915842 27776589 5925 10450 26440 69826 92789 205430 5037 5037 35902898 226450 0.77370 0.79510 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER - 2020 AMOUNT: $ 5,037. 2024 AMOUNT: $ 0. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 0 0 0 0 0 0 1 5521 5521 0 PART II-B, LINE 1: THE FOUNDATION RECEIVES PRO BONO LOBBYING SERVICES FROM AKIN GUMP. THE FOUNDATION HAS TWO MEMBERS OF THE STAFF THAT SUPPORT THE ADVOCACY PROGRAM - DIRECTOR OF ADVOCACY AND ADVOCACY COORDINATOR. ADVOCATE VOLUNTEERS SUPPORT THE FOUNDATION'S WORK AT BOTH THE FEDERAL AND STATE LEVEL. 4226843 1056357 48769 78414 5253555 1582886 2347210 296747 4226843 692547 900391 -7352 2700 1582886 696488 -3941 692547 0.53333 0.42856 0.03812 0 0 202760 120510 82250 486550 356092 130458 212708 RIGHT OF USE ASSET - OPERATING 918309 DONATED PROPERTY HELD FOR SALE 1045538 1963847 OPERATING LEASE LIABILITY 1200876 1200876 X 9221570 -49450 808545 759095 8462475 18589 -1067239 -1048650 7413825 8731547 808545 1067239 1875784 6855763 18589 31422 50011 6905774 PART V, LINE 4: MRF ENDOWMENT ACCOUNT EXPENDITURES WILL COINCIDE WITH THE SAME MISSION STATEMENTS AS THE ORGANIZATION. THE CORPUS OF THE ENDOWMENT FUND, COMPRISED OF THE ORIGINAL GIFT(S) AND ANY SUBSEQUENT GIFTS TO THE FUND, IS TO BE HELD IN PERPETUITY AND MAINTAINED AT THE LEVEL OF THE GIFTS MADE TO THE FUND. PART X, LINE 2: THE FOUNDATION PERFORMED AN EVALUATION OF UNCERTAINTY IN INCOME TAXES FOR THE YEAR ENDED MARCH 31, 2025, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS. PART XI, LINE 4B - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSE -1,067,239. PART XII, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSE 1,067,239. PART XII, LINE 4B - OTHER ADJUSTMENTS: REFUND OF UNUSED GRANT EXPENDITURES 31,422. 1 SOUTH ASIA 0 0 GRANTMAKING 28748 0 0 0 0 0 0 28748 0 28748 SOUTH ASIA TO SUPPORT MELANOMA CANCER RESEARCH 28748 WIRE 0 0 1 0 0 0 0 0 0 PART I, LINE 2: THE MRF'S SCIENTIFIC LEADERSHIP IS COMPRISED OF MULTIDISCIPLINARY EXPERTS IN BASIC AND TRANSLATIONAL RESEARCH, DERMATOLOGY, EPIDEMIOLOGY, GENOMICS, PATHOLOGY, SURGERY AND MEDICAL ONCOLOGY. MEMBERS OF ALL OUR ADVISORY/ STEERING COMMITTEES ARE VOLUNTEERS THAT ASSIST IN PROVIDING THE SCIENTIFIC DIRECTION OF THE MRF. PART I, LINE 3: IN ACCORDANCE WITH IRS INSTRUCTIONS, ALL AMOUNTS REPORTED ON PART I OF SCHEDULE F ARE REPORTED USING THE ACCRUAL BASIS OF ACCOUNTING, THE SAME METHOD OF ACCOUNTING USED IN THE FINANCIAL STATEMENTS. GALAS 1336202 1258202 78000 10535 204142 29755 230039 MILES FOR MELANOMA 1230339 1055586 174753 155852 6054 10627 420235 2566541 2313788 252753 166387 210196 40382 650274 1067239 -814486 1 TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET 5TH FLOOR FRANKLIN BUILDING PHILADELPHIA PA 19104 231352685 501(C)(3) 300000 0 TO SUPPORT MELANOMA CANCER RESEARCH ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 100296574 042263040 501(C)(3) 250000 0 TO SUPPORT MELANOMA CANCER RESEARCH THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY 3601 SPRUCE STREET PHILADELPHIA PA 19104 236434390 501(C)(3) 250000 0 TO SUPPORT MELANOMA CANCER RESEARCH THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BOULEVARD UNIT 1697 HOUSTON TX 77030 316025986 501(C)(3) 110000 0 TO SUPPORT MELANOMA CANCER RESEARCH NEW YORK UNIVERSITY 550 FIRST AVENUE NEW YORK NY 10016 135562308 501(C)(3) 109828 0 TO SUPPORT MELANOMA CANCER RESEARCH THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 809 SOUTH MARSHFIELD AVENUE M/C 551 CHICAGO IL 60612 376000511 501(C)(3) 100000 0 TO SUPPORT MELANOMA CANCER RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 100000 0 TO SUPPORT MELANOMA CANCER RESEARCH EMORY UNIVERSITY 1599 CLIFTON ROAD 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 100000 0 TO SUPPORT MELANOMA CANCER RESEARCH INSTITUTE FOR CANCER RESEARCH DBA THE RESEARCH INSTITUTE OF FOX CHASE CANCE 333 COTTMAN AVENUE PHILADELPHIA PA 19111 236296135 501(C)(3) 100000 0 TO SUPPORT MELANOMA CANCER RESEARCH THE REGENTS OF THE UNIVERSITY CALIFORNIA LOS ANGELES BOX 957089 1125 MURPHY 405 HILGARD AVENUE LOS ANGELES CA 90095 956006143 501(C)(3) 100000 0 TO SUPPORT MELANOMA CANCER RESEARCH WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION ONE WATERFRONT PLACE PO BOX 6005 MORGANTOWN WV 26506 550665758 501(C)(3) 10000 0 TO SUPPORT MELANOMA CANCER RESEARCH CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 510197108 501(C)(3) 6661 0 TO SUPPORT MELANOMA CANCER RESEARCH UNIVERSITY OF ALABAMA OF BIRMINGHAM 801 5TH AVENUE SOUTH ROOM 251 BIRMINGHAM AL 35233 636005396 501(C)(3) 9503 0 TO SUPPORT MELANOMA CANCER RESEARCH UNIVERSITY OF PITTSBURGH 116 ATWOOD STREET SUITE 201 PITTSBURGH PA 15260 250965591 501(C)(3) 5873 0 TO SUPPORT MELANOMA CANCER RESEARCH 14 0 STUDENT MEDICAL AWARDS 15 45000 PART I, LINE 2: THE MRF'S SCIENTIFIC LEADERSHIP IS COMPRISED OF MULTIDISCIPLINARY EXPERTS IN BASIC AND TRANSLATIONAL RESEARCH, DERMATOLOGY, EPIDEMIOLOGY, GENOMICS, PATHOLOGY, SURGERY AND MEDICAL ONCOLOGY. MEMBERS OF ALL OUR ADVISORY/ STEERING COMMITTEES ARE VOLUNTEERS THAT ASSIST IN PROVIDING THE SCIENTIFIC DIRECTION OF THE MRF. X X X 0 0 0 0 0 0 0 1 0 KYLEIGH LIPIRA CEO 329451 0 10832 0 0 0 10111 0 2101 0 352495 0 0 0 JAMES MERRICK CHIEF COMMUNICATIONS OFFICER 159361 0 0 0 0 0 3200 0 9050 0 171611 0 0 0 PART I, LINE 3 THE MOST RECENT COMPENSATION SURVEY WAS COMPLETED ON FEBRUARY 3, 2025. PART I, LINE 7 DURING THE YEAR ENDED DECEMBER 31, 2024, KYLEIGH LIPIRA, CEO, RECEIVED A BONUS PAYMENT IN THE AMOUNT OF $10,832 BASED ON HER PERFORMANCE. ELIZABETH REILLY, SENIOR DEVELOPMENT OFFICER - ENDOWMENT AND PLANNED GIVING, ALSO RECEIVED A BONUS OF $15,600. STAN ADLER ASSOCIATES STAN ADLER, BOARD MEMBER, IS ALSO THE CHAIR AND FOUNDER OF THE ASSOCIATES 107010 MRF PAID A RETAINER FEE TO THE ASSOCIATES FOR GRAPHIC DESIGN AND MARKETING SERVICES. 0 X 3 80501 FMV X UPF SHIRTS 1 120000 FMV X UV SUNSCREEN 1 29600 FMV 0 1 0 PART I, COLUMN (B): THIS COLUMN REPRESENTS THE NUMBER OF ACTUAL CONTRIBUTIONS, NOT THE NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART VI, SECTION B, LINE 11B THE OUTSOURCED ACCOUNTING FIRM AND THE CHIEF EXECUTIVE OFFICER REVIEW THE FEDERAL FORM 990 PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. UPON SUBMISSION OF THE FINAL DRAFT, THE FORM 990 IS DISTRIBUTED TO THE BOARD OF DIRECTORS AND THE FINANCE AND AUDIT COMMITTEE FOR THEIR REVIEW AND APPROVAL PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS DISTRIBUTED ANNUALLY TO ALL MEMBERS OF THE BOARD OF DIRECTORS, KEY PERSONNEL, AND COMMITTEE MEMBERS. EACH RECIPIENT OF THE POLICY RETURNS A SIGNED AND DATED RESPONSE FORM INDICATING THEY REVIEWED THE POLICY WHILE NOTING IF ANY CONFLICTS EXIST. FOLLOWING THE FULL DISCLOSURE OF A POSSIBLE CONFLICT OF INTEREST DURING THE YEAR, THE BOARD OF DIRECTORS WILL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS AND THE BOARD MEMBER WITH THE POSSIBLE CONFLICT WILL RECUSE HIMSELF OR HERSELF FROM THE DISCUSSION AND VOTE. FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER IS DETERMINED BY BOARD EXECUTIVE COMMITTEE AND IS BASED UPON COMPARABLE SALARY DATA. THE BOARD EXECUTIVE COMMITTEE CONVENES AN AD HOC COMPENSATION COMMITTEE THAT CONSULTS WITH AN OUTSIDE EXPERT IN SALARY EVALUATION. APPROPRIATE ADJUSTMENTS ARE MADE TO ENSURE THAT MRF SALARIES ARE IN KEEPING WITH BEST PRACTICES. THE LAST COMPENSATION REVIEW FOR THE CHIEF EXECUTIVE OFFICER WAS CONDUCTED IN 2024. FORM 990, PART VI, SECTION C, LINE 19 MRF'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G CONTRACT SERVICES: PROGRAM SERVICE EXPENSES 544,615. MANAGEMENT AND GENERAL EXPENSES 172,497. FUNDRAISING EXPENSES 173,030. TOTAL EXPENSES 890,142. RECRUITING: PROGRAM SERVICE EXPENSES 50,429. MANAGEMENT AND GENERAL EXPENSES 17,237. FUNDRAISING EXPENSES 7,583. TOTAL EXPENSES 75,249. PAYROLL FEES: PROGRAM SERVICE EXPENSES 15,754. MANAGEMENT AND GENERAL EXPENSES 5,385. FUNDRAISING EXPENSES 2,369. TOTAL EXPENSES 23,508. WEBSITE DESIGN: PROGRAM SERVICE EXPENSES 43,628. MANAGEMENT AND GENERAL EXPENSES 14,985. FUNDRAISING EXPENSES 16,536. TOTAL EXPENSES 75,149. FORM 990, PART XI, LINE 9: REFUNDED GRANTS 31,422.